Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The past 12 months have brought numerous exciting advances involving AI and related emerging technologies. Let us not fail to take a short last look at some of the more spectacular flops.
Some investment analysts are predicting a more permissive M&A market, deregulation as a catalyst for growth and fiscal policies that stimulate economic activity. And they see AI as a catalyst in the shift.
After Luigi Mangione, the man accused of killing UnitedHealthcare CEO Brian Thompson, was extradited to New York, federal prosecutors unsealed a new set of murder charges.
The U.S. Department of Justice said policies at CVS Health forbade pharmacists from discussing patients and providers who may be prescribing opiates in violation of the Controlled Substance Act.
GE HealthCare will be the name of the company’s healthcare business, while its energy portfolio will go under the moniker GE Vernova, and its aviation business will be dubbed GE Aerospace.
The news comes after the New Hampshire Attorney General's Office issued a report that it objected to the merger on the basis that it violates New Hampshire law.
Lisa Mead, PSO executive director, Strategic Radiology, spoke at the Radiology Business Management Association (RBMA) 2022 meeting on her organization's experience collaborating with a large number of radiology groups.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
